Nora Kim
Areas of focus: Medical and surgical weight loss, GLP-1 therapies, and evidence-based supplements.
53 articles on WeightFAQ
- GLP-1 medications
- bariatric surgery
- type 2 diabetes remission
- cardiovascular risk
- night eating syndrome
- sarcopenic obesity
About Nora Kim
Nora Kim is a WeightFAQ staff writer who translates clinical, surgical, and pharmacological weight-loss research into plain-English guidance. She covers the GLP-1 landscape — semaglutide, tirzepatide, and next-generation drugs — alongside bariatric surgery types, post-op nutrition protocols, and revision options. Her articles also address type 2 diabetes remission, cardiovascular risk, PCOS, fatty liver, night eating syndrome, sarcopenic obesity, and how common medications like antipsychotics, statins, and antidepressants affect weight. Nora writes for readers weighing serious clinical decisions and wanting a clear read on evidence, safety, cost, and realistic outcomes.
Articles by Nora Kim (53)
- Weight Loss Blood Tests: The 12 Labs to Ask Your Doctor For (2026 Guide)
The core panel — HbA1c, fasting glucose, lipids, TSH, CBC, CMP, vitamin D — turns up the fixable medical reasons weight loss stalls. Here is the extended list, 2026 US cost, and when to add fasting insulin, ferritin, or a PCOS panel.
- Mounjaro vs Zepbound: Same Drug, Two Brands, Different Insurance in 2026
Mounjaro and Zepbound are both tirzepatide from Eli Lilly, in the same pen at the same doses. The real differences are FDA indication, insurance coverage, and cash-pay pricing in 2026.
- Food Noise: What It Is, Why GLP-1s Quiet It, and What Helps If You're Not on One
Food noise is the intrusive, repetitive thinking about food that GLP-1s famously quiet — here is what it is, why the drugs reduce it, and what evidence-based habits help when medication is not an option.
- Cardiovascular Disease and Weight Loss: What SELECT, Look AHEAD, and the STEP-HFpEF Trials Actually Show About MACE, MI, and Stroke Risk
SELECT showed semaglutide 2.4 mg cut major cardiac events 20% in patients with heart disease and obesity. Look AHEAD did not hit its primary endpoint at group level, but ≥10% loss did. Here's what the trials actually show about weight loss and cardiovascular risk.
- Type 2 Diabetes Remission via Weight Loss: What DiRECT, DIADEM-I, and STAMPEDE Actually Show About the 15 kg Threshold
DiRECT put 46% of participants into remission at 1 year and 36% at 2 years with primary-care VLCD. Here's the ADA/EASD definition, the ~15 kg threshold, and how DIADEM-I and STAMPEDE fit.
- Bariatric Post-Op Vitamin and Nutrition Protocol: The ASMBS 2020 Standard for Sleeve, Bypass, SADI, and Revisions
The ASMBS 2020 lifetime supplement stack after sleeve gastrectomy, gastric bypass, and duodenal switch — dose by procedure, timing rules, standardized labs, and when to go to the ER.
- Continuous Glucose Monitors for Weight Loss: What Stelo, Lingo, Dexcom, and FreeStyle Libre Actually Tell You
A continuous glucose monitor measures interstitial glucose every 1 to 5 minutes. In type 2 and type 1 diabetes it clearly improves outcomes and is standard of care. For weight loss in adults without diabetes the RCT signal is small but real — roughly 1 to 2 kg over 3 to 6 months when paired with behavioural coaching. Stelo (Dexcom, OTC 2024) and Lingo (Abbott, US launch 2024) made CGMs mainstream, and glucose spikes in non-diabetics are mostly normal physiology, not a weight-loss failure signal.
- Saxenda (Liraglutide 3 mg) for Weight Loss: Where the First FDA-Approved GLP-1 Fits After Wegovy and Zepbound
Saxenda (liraglutide 3 mg) delivers roughly 6–8% weight loss over 56 weeks — the FDA benchmark that opened the modern obesity-drug era in 2014, but roughly 40% of what semaglutide 2.4 mg delivers and 30% of tirzepatide 15 mg. It remains the only GLP-1 FDA-approved for adolescents 12+ and holds a legitimate niche when Wegovy or Zepbound are unavailable, contraindicated, or uncovered.
- Orlistat (Xenical, Alli) for Weight Loss: How the Only FDA-Approved Lipase Inhibitor Works and When It Still Makes Sense
Orlistat (Xenical prescription, Alli OTC) blocks about 30% of dietary fat absorption and delivers roughly 3–4 kg placebo-adjusted weight loss at one year — about a quarter of what Wegovy achieves and a fifth of Zepbound — but it is the only OTC option, the only weight-loss drug with no CNS profile, an FDA-approved pediatric option since 2003, and the only pharmacologic weight-loss drug with a four-year outcomes trial (XENDOS) showing a 37% relative reduction in progression to type 2 diabetes.
- Compounded Semaglutide and Tirzepatide in 2026: Safety, Legality, and Quality After the Shortage Ended
Compounded semaglutide and tirzepatide were legal during the 2022–2024 FDA shortages, but both drugs came off the shortage list in late 2024 and mass-produced compounded copies are no longer legal under Section 503A except for narrow clinical-need exceptions. Here is the honest 2026 picture on safety, legality, quality, and how to evaluate a compounding pharmacy.
- Qsymia (Phentermine-Topiramate) for Weight Loss: How the Combination Works and Why It Delivers More Than Phentermine Alone
Qsymia (phentermine-topiramate) delivers roughly 9–11% placebo-adjusted weight loss over 56 weeks — best-in-class of the pre-GLP-1 orals, about 80% of semaglutide 2.4 mg and roughly half of tirzepatide 15 mg — with a REMS teratogenicity program, a real cognitive burden inherited from topiramate, and a DEA Schedule IV constraint inherited from phentermine.
- Contrave (Naltrexone-Bupropion) for Weight Loss: What It Does, Who It Fits, and Where It Falls Short
Contrave (naltrexone-bupropion) delivers roughly 5–6% placebo-adjusted weight loss over 56 weeks — clinically useful, roughly half of semaglutide 2.4 mg and one-third of tirzepatide 15 mg — with a real seizure risk, an opioid-antagonism liability, and a boxed suicidal-behaviour warning inherited from bupropion.
- Dumping Syndrome After Bariatric Surgery: Early, Late, and What Helps
Early dumping is sweats and cramps after meals. Late dumping is hypoglycemia 1–3 hours later. The honest food, drug, and re-operation picture.
- Prediabetes and Weight Loss: How a 7% Loss Cuts Diabetes Risk in Half
About 96M US adults have prediabetes. A 5–7% weight loss cuts type 2 diabetes risk by ~58%. Here is the evidence and a 5-step plan.
- Metabolic Syndrome and Weight Loss: Reverse All 5 Markers
Losing 7 percent body weight reverses metabolic syndrome in about half of adults. Here is the ATP III diagnosis, the dose-response, and the 5-step protocol.
- Chronic Kidney Disease (CKD) and Weight Loss: How Much to Lose to Protect Your Kidneys
Losing 5–10% of body weight slows CKD progression and lowers proteinuria. Here's how much to lose, and how semaglutide changes the math.
- GERD and Weight Loss: How Much to Lose to Calm Heartburn
A 5 to 10 percent body-weight loss cuts reflux symptoms in roughly 80 percent of people. Here is the BMI dose-response, the 6-step protocol, and the sleeve-vs-bypass decision that quietly changes the answer.
- Gallstones and Weight Loss: Why Rapid Loss Triggers Them and How to Prevent Them
Rapid weight loss can trigger gallstones in 10 to 25 percent of people. Here is why it happens, who is at highest risk, and the 5 evidence-based steps that prevent them.
- Weight Loss and Cholesterol: LDL Drops ~2 mg/dL Per Kilogram (2026)
Every kilogram of weight lost drops LDL by ~2 mg/dL and triglycerides by ~7 mg/dL. See the 5–10% threshold, GLP-1 lipid data, and statin decision matrix.
- Sleep Apnea (OSA) and Weight Loss: Why It Matters and How Much to Lose
Obstructive sleep apnea affects an estimated 1 in 4 adults with overweight or obesity and worsens with weight gain — and weight loss is one of the few interventions that genuinely improves it. Here is what OSA is, how it is diagnosed, how much weight loss reduces it, and what the new GLP-1 / tirzepatide data really shows.
- Fatty Liver Disease (NAFLD / MASLD) and Weight Loss: How Much You Need to Lose to Reverse It
Fatty liver disease (renamed MASLD in 2023) affects roughly 1 in 3 US adults and is silently driven by excess body fat, insulin resistance, and added sugar. The good news: a 5 to 10 percent body-weight loss reverses the fat in most people, and a 10 percent loss reverses fibrosis in many. Here is what the disease actually is, how it is diagnosed, and the evidence-based weight-loss path that works.
- High Blood Pressure and Weight Loss: How Much to Lose to Drop Your Numbers
Weight loss is one of the most reliable non-drug ways to lower blood pressure: roughly 1 mmHg of systolic drop per kilogram lost, with a 5 to 10 percent body-weight loss often enough to drop a stage. Here is what the evidence shows, the 5-lever protocol that works, and how to think about medications and DASH.
- GLP-1 Microdosing: What It Is, Who Does It, and What the Evidence Says
GLP-1 microdosing uses 1/4 to 1/8 of the labeled semaglutide or tirzepatide dose, usually for cost, side-effect tolerance, recomposition, or maintenance. Here's what the evidence actually shows, what it does not, and how to think about it honestly in 2026.
- Rebound Weight Gain After Stopping GLP-1: What to Expect and How to Minimize It
In the STEP-1 extension, patients regained about two-thirds of lost weight within 1 year of stopping semaglutide — but planned tapering, lifestyle anchoring, and maintenance dosing each meaningfully change the outcome.
- Insulin Resistance and Weight Loss: How to Recognize It and What Actually Reverses It
Insulin resistance is the most common metabolic reason adults struggle to lose weight. This guide explains how to recognize it, how it is tested, and the four evidence-based approaches that reliably reverse it.
- Menopause and Weight Loss: What Changes and What to Do About It
Menopause shifts where fat is stored and slows muscle maintenance; here's what actually changes, what doesn't, and the realistic playbook for losing weight through perimenopause and beyond.
- GLP-1 Cost and Insurance Coverage in 2026: Ozempic, Wegovy, Mounjaro, Zepbound
What GLP-1 weight loss medications actually cost in 2026, what insurance covers, manufacturer savings programs, compound vs brand pricing, and how telehealth changes the math.
- Diabetes and Weight Loss: A Type 2 Reversal-Focused Guide
Type 2 diabetes responds strongly to weight loss; this guide explains the remission thresholds, what to eat, how GLP-1 medications and metformin fit in, and what to expect realistically.
- Thyroid and Weight Loss: What Hypothyroidism Actually Does to Your Metabolism
Untreated hypothyroidism modestly lowers resting metabolism — roughly 5 to 10 percent, not the ruined-metabolism myth — and once TSH is in range on levothyroxine, weight loss follows normal diet-and-exercise rules.
- PCOS and Weight Loss: A Realistic, Evidence-Based Guide
PCOS makes weight loss harder through insulin resistance and androgen excess, but a 5–10% body-weight loss meaningfully improves cycles, fertility, and metabolic markers — here is what actually works for diet, exercise, sleep, and medication.
- Bariatric Surgery vs GLP-1: Cost, Weight Loss %, and When Each Wins
An honest, evidence-based comparison of bariatric surgery and GLP-1 medications — average weight loss, durability, cost, side effects, and who each is best for.
- Bariatric Surgery Cost and Insurance Coverage: What Weight Loss Surgery Really Costs
What gastric bypass, sleeve, band, ESG, and gastric balloon actually cost in the U.S. — self-pay ranges, what insurance covers, BMI requirements, the approval timeline, and how to handle a denial.
- GLP-1 Weight Loss Medications Compared (2026): Ozempic vs Wegovy vs Mounjaro vs Zepbound
Head-to-head comparison of Ozempic, Wegovy, Mounjaro, and Zepbound — average 15–22% body-weight loss at 68–72 weeks, dosing schedules, side-effect profiles, and 2026 U.S. list prices.
- Bariatric Surgery Types Compared (2026): Gastric Bypass vs Sleeve vs Band vs ESG
Side-by-side comparison of gastric bypass, sleeve, band, ESG, balloon, and revision — typical 1-year weight loss ranges from 10% to 30% of total body weight, with reversibility, recovery time, and cost.
- Mounjaro for Weight Loss: 15-21% Loss in 72-Week Trials
Mounjaro (tirzepatide) is a prescription GIP/GLP-1 injection that produced 15-21% average weight loss over 72 weeks in the SURMOUNT trials.
- Zepbound for Weight Loss: Cost, Results, Side Effects
Zepbound (tirzepatide) for chronic weight management: average results, monthly cost, side effects, candidacy, and how it compares to other GLP-1 drugs.
- Ozempic vs Wegovy: Key Differences Explained
Ozempic vs Wegovy: same molecule (semaglutide) at different max doses—2 mg (T2D) vs 2.4 mg (weight loss). Cost, coverage, and side effects.
- Endoscopic Sleeve Gastroplasty: Procedure & Eligibility
Who qualifies for endoscopic sleeve gastroplasty (ESG)? BMI criteria, candidacy rules, expected results, costs, and how it compares to bariatric surgery.
- Ozempic for Weight Loss: What to Know
Ozempic (semaglutide) for weight loss — how the diabetes GLP-1 works off-label, expected results vs Wegovy, side effects, cost, and safety.
- Wegovy for Weight Loss
Wegovy (semaglutide 2.4 mg) for chronic weight management — how it works, ~15% STEP-1 loss at 68 weeks, side effects, cost, and rebound risk.
- Semaglutide vs Tirzepatide
Semaglutide vs tirzepatide: ~14.9% vs ~20.9% avg loss in pivotal trials, plus SURMOUNT-5 head-to-head, cost, side effects, and who each fits.
- Weight Loss Drug Safety
Weight loss drug safety — GLP-1s, phentermine, Contrave, and Qsymia carry different risks. Side effects, monitoring, and red flags in one guide.
- Tirzepatide for Weight Loss
Tirzepatide is a dual GIP/GLP-1 medication that supports weight loss; explore benefits, risks, and expectations.
- Sleeve Gastrectomy
Sleeve gastrectomy removes about 80% of the stomach, produces roughly 25% total-body-weight loss at one year, and works partly by dropping the hunger hormone ghrelin — here's who qualifies, what recovery looks like, and how it compares to gastric bypass and GLP-1 medications.
- Semaglutide for Weight Loss
Semaglutide for weight loss: ~14.9% avg loss in STEP-1 at 68 weeks. Dosing, safety, cost, and how it compares to tirzepatide.
- Prescription Weight Loss Medications
Prescription weight loss medications — GLP-1s, phentermine, Qsymia, Contrave, and orlistat — compared on efficacy, cost, side effects, and fit.
- Phentermine for Weight Loss
Phentermine is a DEA Schedule IV appetite suppressant that produces roughly 5–10% weight loss over 12 weeks — still the most-prescribed oral obesity drug in the US in 2026 because it costs $15–$40 a month generic. Here is who it fits, the 12-week-rule reality, how it stacks up against GLP-1s, and the cardiovascular monitoring that has to come with it.
- Ozempic Side Effects: Common Side Effects and Adverse Effects
A clear guide to the common side effects of Ozempic—nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite—and the more serious adverse effects to watch for, including pancreatitis, gallbladder disease, and kidney injury.
- GLP-1 Weight Loss Medications Overview
GLP-1 weight loss medications — semaglutide, tirzepatide, and the newer options — deliver 15–22% average loss in trials. Here's how they work, who they fit, and what to expect.
- Gastric Bypass Surgery
Learn how Roux-en-Y gastric bypass works, who it is for, and what to expect before and after surgery.
- Bariatric Surgery Revision
Bariatric surgery revision is a second procedure done for inadequate weight loss, regain, or complications like severe reflux — it carries higher risk than a first surgery, so most 2026 protocols try GLP-1 medications, behavioral therapy, or endoscopic options before returning to the OR.
- Bariatric Surgery Overview
Bariatric surgery — sleeve, bypass, revision — delivers the largest, most durable weight loss when meds aren't enough. Who qualifies and what it costs.
- Adjustable Gastric Banding in 2026: Cost, Results, and Removal Options
How the adjustable gastric band (lap band) works in 2026: typical 15–20% weight loss, cost, insurance, side-by-side comparison with sleeve and bypass, and what to do if you already have one.